12:00 AM
Nov 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ALG-1001: Phase II started

Allegro began a double-blind, placebo-controlled, dose-ranging, international Phase II trial to evaluate intravitreal ALG-1001 in up to 200 patients. Senju has exclusive rights to co-develop and market the...

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >